Literature DB >> 24944757

Device-guided breathing exercises for the treatment of hypertension: An overview.

Kornelis Jj van Hateren1, Gijs Wd Landman1, Susan Jj Logtenberg1, Henk Jg Bilo1, Nanne Kleefstra1.   

Abstract

The American Heart Association considers device-guided breathing as a reasonable treatment modality in their statement on non-pharmacological options for lowering blood pressure. This review discusses all randomized controlled trials that have investigated the effects of device-guided breathing on blood pressure in patients with hypertension. Thirteen studies were included in this review. In total, 627 patients were included, of which 365 patients were allocated to device-guided breathing. Only 6 studies used acceptable control groups: listening to music, meditative relaxation exercises, or a sham-device. Two sponsored trials showed beneficial effects of device-guided breathing, both used listening to music as a control group. The remaining 4 studies, which had no employees of the manufacturer listed as co-author, observed no beneficial effects on blood pressure. There is only 1 study that used a sham device as a control group. All other studies were to some extend methodologically flawed. Based on the studies with an acceptable methodological quality, there is no clear evidence supporting a short-term beneficial effect on blood pressure by using device-guided breathing.

Entities:  

Keywords:  Device-guided breathing; Hypertension; Review

Year:  2014        PMID: 24944757      PMCID: PMC4062130          DOI: 10.4330/wjc.v6.i5.277

Source DB:  PubMed          Journal:  World J Cardiol


  26 in total

1.  Call for a re-evaluation of the American Heart Association's standpoint concerning device-guided slow breathing using the RESPeRATE device.

Authors:  Peter R van Dijk; Gijs W D Landman; Kornelis J J van Hateren; Susan J J Logtenberg; Henk J G Bilo; Nanno Kleefstra
Journal:  Hypertension       Date:  2013-08-19       Impact factor: 10.190

2.  Response to Call for a re-evaluation of the American Heart Association's standpoint concerning device-guided slow breathing using the RESPeRATE device.

Authors:  William J Elliott; Robert D Brook
Journal:  Hypertension       Date:  2013-10       Impact factor: 10.190

3.  Breathing-control lowers blood pressure.

Authors:  E Grossman; A Grossman; M H Schein; R Zimlichman; B Gavish
Journal:  J Hum Hypertens       Date:  2001-04       Impact factor: 3.012

Review 4.  Beyond medications and diet: alternative approaches to lowering blood pressure: a scientific statement from the american heart association.

Authors:  Robert D Brook; Lawrence J Appel; Melvyn Rubenfire; Gbenga Ogedegbe; John D Bisognano; William J Elliott; Flavio D Fuchs; Joel W Hughes; Daniel T Lackland; Beth A Staffileno; Raymond R Townsend; Sanjay Rajagopalan
Journal:  Hypertension       Date:  2013-04-22       Impact factor: 10.190

5.  Treating hypertension with a device that slows and regularises breathing: a randomised, double-blind controlled study.

Authors:  M H Schein; B Gavish; M Herz; D Rosner-Kahana; P Naveh; B Knishkowy; E Zlotnikov; N Ben-Zvi; R N Melmed
Journal:  J Hum Hypertens       Date:  2001-04       Impact factor: 3.012

Review 6.  Autonomic imbalance, hypertension, and cardiovascular risk.

Authors:  R D Brook; S Julius
Journal:  Am J Hypertens       Date:  2000-06       Impact factor: 2.689

Review 7.  Arterial baroreflex function and cardiovascular variability: interactions and implications.

Authors:  Paola A Lanfranchi; Virend K Somers
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2002-10       Impact factor: 3.619

8.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

9.  Nonpharmacologic treatment of hypertension by respiratory exercise in the home setting.

Authors:  Ester Meles; Cristina Giannattasio; Monica Failla; Gaetano Gentile; Anna Capra; Giuseppe Mancia
Journal:  Am J Hypertens       Date:  2004-04       Impact factor: 2.689

10.  Treating hypertension in type II diabetic patients with device-guided breathing: a randomized controlled trial.

Authors:  M H Schein; B Gavish; T Baevsky; M Kaufman; S Levine; A Nessing; A Alter
Journal:  J Hum Hypertens       Date:  2008-11-13       Impact factor: 3.012

View more
  6 in total

1.  Acute effects of device-guided slow breathing on sympathetic nerve activity and baroreflex sensitivity in posttraumatic stress disorder.

Authors:  Ida T Fonkoue; Paul J Marvar; Seth D Norrholm; Melanie L Kankam; Yunxiao Li; Dana DaCosta; Barbara O Rothbaum; Jeanie Park
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-04-13       Impact factor: 4.733

2.  Increased cardio-respiratory coupling evoked by slow deep breathing can persist in normal humans.

Authors:  Thomas E Dick; Joseph R Mims; Yee-Hsee Hsieh; Kendall F Morris; Erica A Wehrwein
Journal:  Respir Physiol Neurobiol       Date:  2014-09-28       Impact factor: 1.931

3.  Comments on: Cernes, R. & Zimlichman, R. Role of Paced Breathing for Treatment of Hypertension. Curr Hypertens Rep (2017) 19: 45.

Authors:  Gijs W D Landman; Kornelis J J van Hateren; Nanne Kleefstra
Journal:  Curr Hypertens Rep       Date:  2017-08       Impact factor: 5.369

Review 4.  Role of Paced Breathing for Treatment of Hypertension.

Authors:  Relu Cernes; Reuven Zimlichman
Journal:  Curr Hypertens Rep       Date:  2017-06       Impact factor: 5.369

5.  Inspiratory Muscle Training Improves Sleep and Mitigates Cardiovascular Dysfunction in Obstructive Sleep Apnea.

Authors:  Jennifer R Vranish; E Fiona Bailey
Journal:  Sleep       Date:  2016-06-01       Impact factor: 5.849

6.  Slow-Paced Breathing and Autonomic Function in People Post-stroke.

Authors:  Mia Larson; Daniel P Chantigian; Ninitha Asirvatham-Jeyaraj; Ann Van de Winckel; Manda L Keller-Ross
Journal:  Front Physiol       Date:  2020-10-30       Impact factor: 4.566

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.